These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7748196)

  • 1. Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1).
    Akunne HC; Demattos SB; Whetzel SZ; Wustrow DJ; Davis DM; Wise LD; Cody WL; Pugsley TA; Heffner TG
    Biochem Pharmacol; 1995 Apr; 49(8):1147-54. PubMed ID: 7748196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional activity of new C-terminal cyclic-neurotensin fragment analogs.
    Akunne HC; Darling S; Zoski K; Sefler AM; He JX; Sawyer TK; Pugsley TA; Cody WL
    Neuropeptides; 1996 Jun; 30(3):213-8. PubMed ID: 8819144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists.
    Pugsley TA; Akunne HC; Whetzel SZ; Demattos S; Corbin AE; Wiley JN; Wustrow DJ; Wise LD; Heffner TG
    Peptides; 1995; 16(1):37-44. PubMed ID: 7716073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotensin receptors on the rat liver plasma membranes.
    Muraki K; Nishi Y; Arai M; Kubo N; Ueda K; Shikata H; Nakata Y; Segawa T; Yanaihara N; Yajima H
    Biochem Biophys Res Commun; 1987 Jun; 145(3):1071-9. PubMed ID: 3038090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurotensin modulates the electrical activity of frog pituitary melanotropes via activation of a G-protein-coupled receptor pharmacologically related to both the NTS1 and nts2 receptors of mammals.
    Belmeguenai A; Vaudry H; Leprince J; Vivet B; Cavelier F; Martinez J; Louiset E
    Neuroendocrinology; 2000 Dec; 72(6):379-91. PubMed ID: 11146421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LANT-6, xenopsin and neuromedin N stimulate cyclic GMP at neurotensin receptors.
    Gilbert JA; Richelson E
    Eur J Pharmacol; 1986 Oct; 129(3):379-83. PubMed ID: 3023108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of neurotensin receptors and purinoceptors in human colonic adenocarcinoma cells detected with the microphysiometer.
    Richards M; van Giersbergen P; Zimmermann A; Lesur B; Hoflack J
    Biochem Pharmacol; 1997 Oct; 54(7):825-32. PubMed ID: 9353137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human umbilical vein endothelial cells express high affinity neurotensin receptors coupled to intracellular calcium release.
    Schaeffer P; Laplace MC; Savi P; Pflieger AM; Gully D; Herbert JM
    J Biol Chem; 1995 Feb; 270(7):3409-13. PubMed ID: 7852427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct functional characteristics of levocabastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells.
    Yamada M; Yamada M; Lombet A; Forgez P; Rostène W
    Life Sci; 1998; 62(23):PL 375-80. PubMed ID: 9627096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and structure-activity relationships of C-terminal cyclic neurotensin fragment analogues.
    Sefler AM; He JX; Sawyer TK; Holub KE; Omecinsky DO; Reily MD; Thanabal V; Akunne HC; Cody WL
    J Med Chem; 1995 Jan; 38(2):249-57. PubMed ID: 7830267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the terminal homologation of physiologically active peptides as a means of increasing stability in human serum--neurotensin, opiorphin, B27-KK10 epitope, NPY.
    Seebach D; Lukaszuk A; Patora-Komisarska K; Podwysocka D; Gardiner J; Ebert MO; Reubi JC; Cescato R; Waser B; Gmeiner P; Hübner H; Rougeot C
    Chem Biodivers; 2011 May; 8(5):711-39. PubMed ID: 21560227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
    Labbé-Jullié C; Botto JM; Mas MV; Chabry J; Mazella J; Vincent JP; Gully D; Maffrand JP; Kitabgi P
    Mol Pharmacol; 1995 May; 47(5):1050-6. PubMed ID: 7746272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity and conformational studies of a series of modified C-terminal hexapeptide neurotensin analogues.
    Heyl DL; Sefler AM; He JX; Sawyer TK; Wustrow DJ; Akunne HC; Davis MD; Pugsley TA; Heffner TG; Corbin AE
    Int J Pept Protein Res; 1994 Sep; 44(3):233-8. PubMed ID: 7822099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotensin and neuromedin N elevate the cytosolic calcium concentration via transiently appearing neurotensin binding sites in cultured rat cortex cells.
    Sato M; Shiosaka S; Tohyama M
    Brain Res Dev Brain Res; 1991 Jan; 58(1):97-103. PubMed ID: 1849803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.
    Labbé-Jullié C; Dubuc I; Brouard A; Doulut S; Bourdel E; Pelaprat D; Mazella J; Martinez J; Rostène W; Costentin J
    J Pharmacol Exp Ther; 1994 Jan; 268(1):328-36. PubMed ID: 8301574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist.
    Sarhan S; Hitchcock JM; Grauffel CA; Wettstein JG
    Peptides; 1997; 18(8):1223-7. PubMed ID: 9396065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of binding sites of a new neurotensin receptor antagonist, [3H]SR 142948A, in the rat brain.
    Betancur C; Canton M; Burgos A; Labeeuw B; Gully D; Rostène W; Pélaprat D
    Eur J Pharmacol; 1998 Feb; 343(1):67-77. PubMed ID: 9551716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for biological activity of two N-terminal fragments of neurotensin, neurotensin1-8 and neurotensin1-10.
    Hernandez DE; Richardson CM; Nemeroff CB; Orlando RC; St-Pierre S; Rioux F; Prange AJ
    Brain Res; 1984 May; 301(1):153-6. PubMed ID: 6329440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier.
    Bredeloux P; Cavelier F; Dubuc I; Vivet B; Costentin J; Martinez J
    J Med Chem; 2008 Mar; 51(6):1610-6. PubMed ID: 18321036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist.
    Gully D; Labeeuw B; Boigegrain R; Oury-Donat F; Bachy A; Poncelet M; Steinberg R; Suaud-Chagny MF; Santucci V; Vita N; Pecceu F; Labbé-Jullié C; Kitabgi P; Soubrié P; Le Fur G; Maffrand JP
    J Pharmacol Exp Ther; 1997 Feb; 280(2):802-12. PubMed ID: 9023294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.